|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Pituitary and hypothalamic somatostatin receptor subtype messenger ribonucleic acid expression in the food-deprived and diabetic rat.
|
7956902 |
1994 |
|
Pancreatic Neoplasm
|
0.310 |
AlteredExpression
|
disease |
LHGDN |
Somatostatin receptor-1 induces cell cycle arrest and inhibits tumor growth in pancreatic cancer.
|
18823376 |
2008 |
|
Adenoma
|
0.040 |
Biomarker
|
group |
LHGDN |
These results demonstrate that SSTR1 selective activation inhibits hormone secretion and cell viability in GH- and PRL-secreting adenomas in vitro and suggest that SRIF analogs with affinity for SSTR1 may be useful to control hormone hypersecretion and reduce neoplastic growth of pituitary adenomas.
|
12788890 |
2003 |
|
Prostatic Neoplasms
|
0.020 |
AlteredExpression
|
group |
LHGDN |
Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines.
|
12474541 |
2002 |
|
Prostatic Neoplasms
|
0.020 |
Biomarker
|
group |
LHGDN |
Identification of prognostic biomarkers for prostate cancer.
|
18347174 |
2008 |
|
Thyroid Neoplasm
|
0.020 |
Biomarker
|
disease |
LHGDN |
Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.
|
12359227 |
2002 |
|
Pituitary Neoplasms
|
0.010 |
Biomarker
|
group |
LHGDN |
Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
|
12788890 |
2003 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
CTD_human |
Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
|
17625444 |
2007 |
|
Pancreatic Neoplasm
|
0.310 |
Biomarker
|
disease |
CTD_human |
Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
|
17625444 |
2007 |
|
Neuroendocrine Tumors
|
0.310 |
Biomarker
|
group |
CTD_human |
Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
|
17625444 |
2007 |
|
Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
SSTR1 and SSTR4 immunoreactivities were increased in the hippocampus at 1 week after SE.
|
18951627 |
2009 |
|
Petit mal status
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Grand Mal Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Complex Partial Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Status Epilepticus, Subclinical
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Non-Convulsive Status Epilepticus
|
0.300 |
Biomarker
|
disease |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Simple Partial Status Epilepticus
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The expression of somatostatin receptors in the hippocampus of pilocarpine-induced rat epilepsy model.
|
18951627 |
2009 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
BEFREE |
SSTR-2, SSTR-5, and SSTR-1 are thought to play major roles in inhibiting pancreatic cancer growth both in vitro and in vivo.
|
15706439 |
2005 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
BEFREE |
This study suggests that gene therapy with SSTR-1 may be a potential adjuvant treatment for pancreatic cancer.
|
18823376 |
2008 |
|
Neuroendocrine Tumors
|
0.310 |
Biomarker
|
group |
BEFREE |
Analysis of mRNA expression of the SSTR subtypes showed that SSTR2 and SSTR5 were expressed in all of the studied NETs; SSTR1 and SSTR4 in all but 3 tumors (86%); and SSTR3 in only 10 NETs (49%).
|
20423238 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SSTR1 and SSTR2 were, respectively, expressed in 3 of 7 and 9 of 10 GH-secreting tumors, 1 of 9 and 5 of 9 nonfunctioning tumors, 4 of 5 and 0 of 5 of prolactinomas, and 1 of 3 and 0 of 3 ACTH-secreting tumors.
|
8106629 |
1994 |
|
Neoplasms
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
SSTR1 hypermethylation in 64% of cases was correlated with tumor size (P = 0.037), stage (P = 0.037), SST methylation (P < 0.001), and expression of galanin (P = 0.03), GALR2 (P = 0.014), TAC1 (P = 0.023), and tachykinin receptor type 1 (TACR1) (P = 0.003).
|
25734919 |
2015 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of SSTR5 was detected in approximately one-third of tumour and normal tissue, but fewer than 13% of all tissues expressed SSTR1, 3 and 4.
|
9062398 |
1997 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
SSTR1 gene expression was seen in several human and rat tumor types, and SSTR3 gene expression observed in two rodent tumor types.
|
8515684 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunoreactivity of sstr1, sstr2a and sstr4 tended to decrease as tumor aggressiveness increased. sstr5 showed an opposite pattern, with higher staining in well-differentiated carcinomas compared with well-differentiated tumors. sstr5 immunoreactivity was correlated with the presence of metastases and angioinvasion, suggesting a possible association with more aggressive behavior.
|
22156600 |
2012 |